The clinical trial report, “Rheumatoid Arthritis - Global Clinical Trials Review, 2026" provides an overview of Rheumatoid Arthritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Rheumatoid Arthritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Rheumatoid Arthritis to Immunology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Rheumatoid Arthritis to Immunology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Rheumatoid Arthritis Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Rheumatoid Arthritis
- Jan 12, 2026: Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
- Jan 08, 2026: AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
- Jan 07, 2026: Nucleome Therapeutics Nominates First Preclinical Development Candidate
- Dec 12, 2025: Shanghai Fosun : Announcement in Relation to the Approval of Ketoprofen Drug Clinical Trial of a Subsidiary
- Dec 03, 2025: Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 Inhibitor O3R-5671
- Nov 03, 2025: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion
- Oct 30, 2025: Lipum Presents New Topline Data Supporting BSSL’s Role in Rheumatoid Arthritis
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Region, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Rheumatoid Arthritis to Immunology Clinical Trials, G7 Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Rheumatoid Arthritis to Immunology Clinical Trials, E7 Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Phase, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Rheumatoid Arthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Rheumatoid Arthritis to Immunology Clinical Trials, G7 Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Rheumatoid Arthritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Rheumatoid Arthritis to Immunology Clinical Trials, E7 Countries (%), 2026*
- Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Rheumatoid Arthritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Rheumatoid Arthritis Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Rheumatoid Arthritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Rheumatoid Arthritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Roche Holding AG
- Pfizer Inc
- AbbVie Inc
- Bristol-Myers Squibb Co
- Johnson & Johnson
- Amgen Inc
- AstraZeneca Plc
- Eli Lilly and Co
- UCB SA
- C. H. Boehringer Sohn AG & Co KG
